R R Edwards1, A J Dolman2, E Michna2, J N Katz3, S S Nedeljkovic2, D Janfaza2, Z Isaac4, M O Martel2, R N Jamison5, A D Wasan6. 1. *Department of Anesthesiology, rredwards@partners.org. 2. *Department of Anesthesiology. 3. Department of Internal Medicine and Orthopedic Surgery. 4. Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, and. 5. Department of Anesthesiology and Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. 6. Department of Anesthesiology and Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Abstract
OBJECTIVE:Opioids are frequently prescribed for chronic low back pain (CLBP), but there are broad individual differences in the benefits and risks of opioid therapy, including the development opioid-induced hyperalgesia. This study examined quantitative sensory testing (QST) data among a group of CLBP patients undergoing sustained oral opioid treatment. We investigated whether individual differences in psychological characteristics were related to opioid-induced changes in pain perception and pain modulation. DESIGN: The six-month, open-label trial evaluated patients with low to high levels of negative affect (e.g., symptoms of distress, depression and anxiety); participants underwent QST at baseline (prior to initiating treatment) and during oral opioid treatment. SETTING: A chronic pain management center. PATIENTS: The 31 study participants had chronic discogenic back pain, with a pain intensity rating >3/10. Participants were divided into groups with high vs. low levels of Negative Affect (NA). RESULTS: In the previously-published manuscript describing the clinical outcomes of the trial, high NA patients achieved only about half of the analgesic effect observed in the low NA group (Wasan AD, Michna E, Edwards RR, et al. Psychiatric comorbidity is associated prospectively with diminished opioid analgesia and increased opioid misuse in patients with chronic low back pain. Anesthesiology 2015;123:861-72). The QST findings reported here suggested that tolerance to experimental (cold pressor) pain and conditioned pain modulation tended to decrease in the high NA group over the course of opioid treatment, while temporal summation of mechanical pain declined in the low NA group. CONCLUSIONS: These results reveal that while the low NA group seemed to exhibit a generally adaptive, analgesic pattern of changes during opioid management, the high NA group showed a pattern more consistent with opioid-induced hyperalgesic processes. A greater susceptibility to hyperalgesia-promoting changes in pain modulation among patients with high levels of distress may contribute to a lower degree of benefit from opioid treatment in high NA patients.
RCT Entities:
OBJECTIVE: Opioids are frequently prescribed for chronic low back pain (CLBP), but there are broad individual differences in the benefits and risks of opioid therapy, including the development opioid-induced hyperalgesia. This study examined quantitative sensory testing (QST) data among a group of CLBP patients undergoing sustained oral opioid treatment. We investigated whether individual differences in psychological characteristics were related to opioid-induced changes in pain perception and pain modulation. DESIGN: The six-month, open-label trial evaluated patients with low to high levels of negative affect (e.g., symptoms of distress, depression and anxiety); participants underwent QST at baseline (prior to initiating treatment) and during oral opioid treatment. SETTING: A chronic pain management center. PATIENTS: The 31 study participants had chronic discogenic back pain, with a pain intensity rating >3/10. Participants were divided into groups with high vs. low levels of Negative Affect (NA). RESULTS: In the previously-published manuscript describing the clinical outcomes of the trial, high NA patients achieved only about half of the analgesic effect observed in the low NA group (Wasan AD, Michna E, Edwards RR, et al. Psychiatric comorbidity is associated prospectively with diminished opioid analgesia and increased opioid misuse in patients with chronic low back pain. Anesthesiology 2015;123:861-72). The QST findings reported here suggested that tolerance to experimental (cold pressor) pain and conditioned pain modulation tended to decrease in the high NA group over the course of opioid treatment, while temporal summation of mechanical pain declined in the low NA group. CONCLUSIONS: These results reveal that while the low NA group seemed to exhibit a generally adaptive, analgesic pattern of changes during opioid management, the high NA group showed a pattern more consistent with opioid-induced hyperalgesic processes. A greater susceptibility to hyperalgesia-promoting changes in pain modulation among patients with high levels of distress may contribute to a lower degree of benefit from opioid treatment in high NA patients.
Authors: Miroslav Misha Backonja; Nadine Attal; Ralf Baron; Didier Bouhassira; Mark Drangholt; Peter J Dyck; Robert R Edwards; Roy Freeman; Richard Gracely; Maija H Haanpaa; Per Hansson; Samar M Hatem; Elena K Krumova; Troels S Jensen; Christoph Maier; Gerard Mick; Andrew S Rice; Roman Rolke; Rolf-Detlef Treede; Jordi Serra; Thomas Toelle; Valeri Tugnoli; David Walk; Mark S Walalce; Mark Ware; David Yarnitsky; Dan Ziegler Journal: Pain Date: 2013-06-03 Impact factor: 6.961
Authors: Chantal Berna; Siri Leknes; Emily A Holmes; Robert R Edwards; Guy M Goodwin; Irene Tracey Journal: Biol Psychiatry Date: 2010-03-29 Impact factor: 13.382
Authors: Roger B Fillingim; Barbara A Hastie; Timothy J Ness; Toni L Glover; Claudia M Campbell; Roland Staud Journal: Biol Psychol Date: 2004-12-25 Impact factor: 3.251
Authors: Stephen F Butler; Simon H Budman; Kathrine C Fernandez; Brian Houle; Christine Benoit; Nathaniel Katz; Robert N Jamison Journal: Pain Date: 2007-05-09 Impact factor: 6.961
Authors: Junie S Carriere; Marc Olivier Martel; Samantha M Meints; Marise C Cornelius; Robert R Edwards Journal: Eur J Pain Date: 2019-01-09 Impact factor: 3.931
Authors: Daniel E Harper; Eric Ichesco; Andrew Schrepf; Johnson P Hampson; Daniel J Clauw; Tobias Schmidt-Wilcke; Richard E Harris; Steven E Harte Journal: J Pain Date: 2018-01-31 Impact factor: 5.820
Authors: Thiago Gagliano-Jucá; Thomas G Travison; Paul L Nguyen; Philip W Kantoff; Mary-Ellen Taplin; Adam S Kibel; Robert Manley; Kathleen Hally; Richelle Bearup; Yusnie M Beleva; Grace Huang; Robert R Edwards; Shehzad Basaria Journal: J Pain Symptom Manage Date: 2017-09-21 Impact factor: 3.612
Authors: Eric L Garland; Craig J Bryan; Yoshio Nakamura; Brett Froeliger; Matthew O Howard Journal: Psychopharmacology (Berl) Date: 2016-12-08 Impact factor: 4.530